Post-essential Thrombocythemia Myelofibrosis
📧 Sign up to get email alerts when something new happens for Post-essential Thrombocythemia Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) [Phase 1, Phase 2]
Clinical trial update for Bomedemstat (IMG-7289/MK-3543) in myelofibrosis showing completion and posted results for Phase 1/2 study.
-
CLINICAL_TRIALS trial_result · 2023-05-23Clinical Trial Update: Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF [Phase 3]
Phase 3 trial comparing momelotinib to best available therapy in anemic or thrombocytopenic patients with various subtypes of myelofibrosis;…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis [Phase 3]
Phase 3 trial comparing momelotinib to ruxolitinib in myelofibrosis subjects has completed with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment [Phase 2, Phase 3]
Clinical trial updating the efficacy of KRT-232 versus best available therapy for relapsed/refractory myelofibrosis (Phase 2/Phase 3).
-
CLINICAL_TRIALS trial_result · 2023-04-20Clinical Trial Update: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating jaktinib for patients with myelofibrosis intolerant to ruxolitinib has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]
A Phase 3 trial of fedratinib in patients with primary myelofibrosis and myelofibrosis after polycythemia vera or essential thrombocythemia …
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) [Phase 3]
Phase 3 trial comparing momelotinib to danazol in symptomatic and anemic myelofibrosis has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-01Clinical Trial Update: Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib [Phase 2]
Phase 2 dose-finding study of pacritinib in myelofibrosis patients previously treated with ruxolitinib has completed; results posted in 2022…
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis [Phase 2]
Phase 2 trial evaluating KRT-232 or TL-895 in JAK inhibitor–treated myelofibrosis patients remains in status unknown.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) [Phase 1]
Phase 1 study of oral ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocyt…
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF [Phase 1, Phase 2]
Phase 1/2 safety and tolerability trial of oral NS-018 in myelofibrosis patients completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: A Phase 2 Study of RO7490677 In Participants With Myelofibrosis [Phase 2]
Phase 2 clinical trial update for RO7490677 in myeloproliferative neoplasms has completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2021-11-18Clinical Trial Update: Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia [Phase 3]
Phase 3 trial comparing pacritinib to best available therapy in myelofibrosis with thrombocytopenia was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-21Clinical Trial Update: PD-1 Inhibition in Advanced Myeloproliferative Neoplasms [Phase 2]
Phase 2 trial assessing PD-1 inhibition in advanced myeloproliferative neoplasms has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 long-term safety and efficacy update for momelotinib in various myelofibrosis subtypes; study completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) [Phase 2]
Phase 2 trial update for momelotinib in transfusion-dependent adults with primary myelofibrosis and related post-PV/ET myelofibrosis; trial …
-
CLINICAL_TRIALS trial_result · 2020-09-29Clinical Trial Update: Pacritinib Versus Best Available Therapy to Treat Myelofibrosis [Phase 3]
Phase 3 trial comparing pacritinib to best available therapy in myelofibrosis was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-04-30Clinical Trial Update: Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. [Phase 2]
Phase 2 trial update on the efficacy and safety of ruxolitinib in treating anemic myelofibrosis, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) [Phase 2]
Phase 2 trial assessing ruxolitinib (INCB018424) in participants with primary myelofibrosis and related post-MPN myelofibrosis conditions ha…
-
CLINICAL_TRIALS trial_result · 2019-09-03Clinical Trial Update: Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF [Phase 2]
Phase II clinical trial update for INC424 (sonidegib) in various myelofibrosis subtypes has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-03-20Clinical Trial Update: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis [Phase 2]
Phase 2 trial evaluating ruxolitinib before transplant in myelofibrosis was terminated; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-04Clinical Trial Update: Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [Phase 2]
This is a Phase 2 extension study evaluating the long-term safety and efficacy of CYT387 (momelotinib) in patients with primary myelofibrosi…
-
CLINICAL_TRIALS trial_result · 2019-02-04Clinical Trial Update: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]
A Phase 1/2 safety study evaluating twice-daily momelotinib in myelofibrosis populations has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [Phase 1, Phase 2]
This update reports the completion of a Phase 1/2 safety and efficacy study of CYT387 in primary myelofibrosis and myelofibrosis following p…
-
CLINICAL_TRIALS trial_result · 2018-04-02Clinical Trial Update: Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib [Phase 2]
A Phase 2 trial of single-agent glasdegib in myelofibrosis patients previously treated with ruxolitinib was terminated; results were posted …